John Girod, MD
Infectious Disease · Salem, ORNPI 1568546794
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 36 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AbbVie at 24.8% of the total. Reporting peaked in 2021 at $172 and has fallen 90.0% since, to $17 in 2025.
Across 36 payments — averaging $21.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$189
- Amgen$182
- Gilead$92
- Tetraphase Pharmaceuticals, Inc.$76
- Smith+Nephew$41
- Theratechnologies Inc.$32
- plus $151 from 8 others
What the payments were for
- Food & beverage$763100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 10 | $189 |
| Amgen | 9 | $182 |
| Gilead | 4 | $92 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $76 |
| Smith+Nephew | 1 | $41 |
| Theratechnologies Inc. | 2 | $32 |
| Astellas Pharma US Inc | 1 | $29 |
| Merck | 2 | $24 |
| Cvrx, Inc. | 1 | $20 |
| Octapharma USA, Inc. | 1 | $19 |
| Pfizer | 1 | $16 |
| Bristol Myers Squibb | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
How this compares
$763 in reported general payments places this provider in the 85th percentile of 90 infectious disease providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atovaquone-Proguanil HclAtovaquone/Proguanil Hcl | 34 | $2,244 |
| CeftriaxoneCeftriaxone Sodium | 23 | $1,134 |
| Azithromycin | 41 | $161 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Salem
- Jasmin ChaudharySalem$4K
- Shara Ann CabreraSalem$3K
- Zoe MullerSalem$472
- Harry ScholtzSalem$322
- Tamara BininashviliSalem$216
- Richard BasilanSalem$116
- Cliffton BongSalem$38
- Kevin WinthropPortland$1.8M
- Tobias PuschPortland$208K
- Wendi DrummondPortland$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.